申请人:Genentech, Inc.
公开号:US09440976B2
公开(公告)日:2016-09-13
The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
本发明涉及式(I)、(I-a)和(I-b)的1,7-二氮杂咔唑化合物,其可用作激酶抑制剂,更具体地,可用作检查点激酶1(chk1)抑制剂,因此可用作癌症治疗药物。本发明还涉及包含这些化合物的组合物,更具体地,是包含这些化合物的药物组合物以及使用这些化合物治疗各种形式的癌症和高增殖性疾病的方法,以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗,或相关病理条件的方法。